Free Newsletter
Nobel winners frustrated, hopeful about AIDS vax
The French scientist Francoise Barre-Sinoussi, who was awarded a Nobel Prize for her work involving the discovery of HIV, tells the AP that the quest to find a vaccine to guard against AIDS has been "a succession of failures." But when they first made their breakthrough 25 years ago, she said they felt that scientists would soon be able to stop the deadly epidemic that has since claimed millions of lives worldwide.
"We naively thought that the discovery of the virus would allow us to quickly learn more about it, to develop diagnostic tests--which has been done--and to develop treatments, which has also been done to a large extent and, most of all, develop a vaccine that would prevent the global epidemic," she said.
But her colleague and co-winner of the Nobel Prize, Luc Montagnier, says that he believes that a new therapeutic vaccine will be available within four years--provided there is enough financial support for the work that's needed.
"I think it'll be possible with a therapeutic vaccine rather than preventative vaccinations. We would give it only to people who are already infected," the French scientist told the Telegraph.
- read the story in the International Herald Tribune
- read the report in the Business Standard
Related Articles:
VGX Pharma gets $23M NIH grant for HIV vax
Scripps wins $30M for HIV research center
Woman's immune system may be key to HIV vax
Fauci says HIV vaccine requires a new approach
IAVI maps out a new route to AIDS vaccine
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession





SHARE
WITH: